Immuno-Oncology News Articles

Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC
Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer, all of which echo similar conclusions: these combinations are a mainstay in this population.
Controversy Adds Caution to CRISPR Editing in United States
The development of cancer treatments and diagnostic tools using CRISPR/Cas9 and other gene-editing technology is a promising area of research in the United States, although the field is moving into human studies at a relatively slow pace.
The FDA has accepted a supplemental biologics license application for atezolizumab, carboplatin, and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer.
Grivas Discusses Developments in Bladder Cancer
Petros Grivas, MD, PhD, discusses the rapidly evolving field of locally advanced and metastatic bladder cancer.
Nivolumab/Ipilimumab Combo Approved in Europe for Frontline RCC
The European Commission has approved nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.
Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC
Sumanta K. Pal, highlights the different combination regimens that are making headlines in the treatment of patients with metastatic renal cell carcinoma.
YOUR Cancer Awards Spotlight Oncology HCPs and Community
Advancing cancer care requires more than just science. It’s a collective effort driven by passionate individuals and organizations dedicated to making a difference for those living with and affected by cancer.
Checkpoint Inhibitors Herald New Era in Urothelial Cancer
Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.
Kwok-Kin Wong, MD, PhD, discusses updates in non–small cell lung cancer and the importance of enrolling patients in clinical trials to further progress the field.
Bellmunt Addresses Immunotherapy Advances, Challenges in Bladder Cancer
Joaquim Bellmunt, MD, PhD, provides insight on how to navigate the complex treatment paradigm of metastatic bladder cancer.
Publication Bottom Border
Border Publication